FREE Daily Stock Alerts From Stock-PR.com
Qiagen NV (NASDAQ:QGEN) announced that it has entered into a partnership with Eli Lilly and Company for the development, manufacturing and commercialization of a molecular companion diagnostic for an early stage investigational compound currently being developed by Lilly. Financial terms of the agreement were not disclosed.
QIAGEN N.V., through its subsidiaries, provides sample and assay technologies. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.
Read full article and disclaimer at : http://stock-pr.com/?p=19983